Document Detail


Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.
MedLine Citation:
PMID:  7660446     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have treated 10 patients suffering from kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) at a dose of 2 mg/kg/d for 5 d, following an earlier study in which this dosage for 7 d was found to cure all of 9 patients, with no relapse during 12 months. In the present study, all patients demonstrated initial resolution of disease. Parasites were absent upon bone marrow re-aspiration 2 weeks after therapy; no spleen extended beyond the costal margin 2 months after therapy; white blood cell counts, platelet counts, and serum levels of albumin rapidly returned to normal. Although one patient relapsed at 5 months, 8 of the other 9 patients had spleens of normal size (undetectable on deep palpation) at 12 months after therapy. Fever, sometimes accompanied by increased respiratory rate, occurred on the first day of drug infusion in 8 of 10 patients and was more severe in patients < 6 years old. Pre-medication with a non-steroidal anti-inflammatory agent (diclofenac potassium) before the next 4 infusions protected against this side effect in 5 of 6 patients. The results of this and our previous study suggest that the most appropriate regimen of Amphocil for kala-azar is 2 mg/kg/d for 7 d, with pre-medication each day, in patients aged > 5 years.
Authors:
R Dietze; S M Fagundes; E F Brito; E P Milan; T F Feitosa; F A Suassuna; G Fonschiffrey; G Ksionski; J Dember
Related Documents :
8286736 - A phase i/ii study of sequential interleukin-3 and granulocyte-macrophage colony-stimul...
19890786 - Allogeneic stem cell transplantation for pediatric and adolescent patients with cml: re...
7794776 - Dapsone for refractory chronic idiopathic thrombocytopenic purpura.
11597376 - Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical gm-...
24026566 - Outcomes of second self-expandable metallic stent insertion for malignant gastric outle...
23747956 - Rehabilitation outcome of anoxic-ischaemic encephalopathy survivors with prolonged diso...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transactions of the Royal Society of Tropical Medicine and Hygiene     Volume:  89     ISSN:  0035-9203     ISO Abbreviation:  Trans. R. Soc. Trop. Med. Hyg.     Publication Date:    1995 May-Jun
Date Detail:
Created Date:  1995-10-04     Completed Date:  1995-10-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7506129     Medline TA:  Trans R Soc Trop Med Hyg     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  309-11     Citation Subset:  IM    
Affiliation:
Unit of Infectious Diseases, Federal University of Espirito Santo, Vitoria, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Amphotericin B / adverse effects,  analogs & derivatives*,  therapeutic use
Antiprotozoal Agents / adverse effects,  therapeutic use*
Brazil
Child
Child, Preschool
Cholesterol Esters / adverse effects,  therapeutic use*
Diclofenac / therapeutic use
Female
Fever / prevention & control
Humans
Infant
Leishmaniasis, Visceral / drug therapy*
Male
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 0/Cholesterol Esters; 1397-89-3/Amphotericin B; 15307-86-5/Diclofenac

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of resistance to chloroquine by Plasmodium vivax in Myanmar.
Next Document:  Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan.